News

Long-term antibiotic treatment, aimed at altering the bacterial population in the gut, was found to reduce the inflammation and amyloid plaque formation that is a hallmark of Alzheimer’s disease — but only in male mice. The same treatment had no effect on female mice, a study found. The…

Genentech, a subsidiary of Roche, has launched a new substudy to learn more about the progression of early-onset familial Alzheimer’s disease, as part of its ongoing Alzheimer’s Prevention Initiative (API)…

A Phase 2a trial testing Oryzon’s investigational therapy vafidemstat for Alzheimer’s disease has enrolled its first patient in the U.S. The trial (NCT03867253), called ETHERAL-US, is an extension of the European trial (2017-004893-32), currently ongoing at 17 sites in the U.K., France, and Spain. Oryzon is…

A vaccine produced using virus-like particles was able to improve cognitive functioning and reduce the accumulation of tau protein aggregates — a hallmark of Alzheimer’s disease — in a mouse model of the disease, a study shows. The study, “Qß Virus-like particle-based vaccine induces robust immunity and protects against…

A connection discovered between Alzheimer’s and the bacteria that cause gum disease suggests that improved oral hygiene may decrease the risk of developing the disorder, a study reports. The study, “Porphyromonas gingivalis in Alzheimer’s disease brains: Evidence for disease causation and treatment with small-molecule inhibitors,” was…

AxoSim has acquired exclusive rights to lab-grown brain miniatures, coined “Mini-Brain,” a technology developed at Johns Hopkins University that uses stem cells to create models of the human brain in a dish. The technique may help speed therapy discovery for many neurological diseases, including Alzheimer’s disease. “Acquiring rights…

Scores of efforts to mark June’s Alzheimer’s & Brain Awareness Month are designed to raise funds and visibility around the degenerative brain disease and related disorders, and the estimated 50 million people worldwide thought to be affected. Across the United States, patients, caregivers, and advocates will “go…

High levels of “bad” cholesterol, known as low-density lipoprotein (LDL), might increase the risk of developing early-onset Alzheimer’s disease, a study suggests. The study, “Association of Early-Onset Alzheimer Disease With Elevated Low-density Lipoprotein Cholesterol Levels and Rare Genetic Coding Variants of APOB,” was published in the journal…

ProMIS Neurosciences’ candidate PMN310 can specifically target toxic clusters of soluble amyloid-beta protein, and be safely administered at high doses with reduced risk of characteristic Alzheimer’s brain changes or swelling, according to clinical data. PMN310 has the potential for greater therapeutic potency compared with other amyloid-beta-directed antibodies…

Selected through the Alzheimer’s Drug Discovery Foundation’s (ADDF) Diagnostics Accelerator program, four scientists will share nearly $3.5 million to develop new biomarkers for early detection of Alzheimer’s disease and related dementia. Philanthropists, including ADDF co-founder Leonard Lauder, Bill Gates and Jeff and MacKenzie Bezos,…